New Chinese vaccine against coronavirus is preparing to enter the market
Topics: Epidemic, Worldwide, Vaccines
According to RIA Novosti, the State Food and Drug Administration has approved the entry into the market of an inactivated vaccine against coronavirus by Sinopharm. According to the developers, this vaccine, when administered twice, made it possible to produce high titer antibodies. Tests have shown that the vaccine is 79.34% effective.
The vaccine complies with the requirements of the State Food and Drug Administration and the World Health Organization (WHO). Despite this, scientists admit that more surveillance is required on the duration of immunity and the effectiveness of the vaccine. Although the Chinese vaccine was one of the first in the world, clinical trials were slowed down because at the time the third phase of trials began, there was virtually no virus in China. Therefore, it was required to carry out this stage mainly in other countries.
Sinopharm chairman of the board of directors Liu Jingzhen notes that approximately 1 million people have received the inactivated vaccine. It is also known that two inactivated vaccines against coronavirus infection, developed by the company, are already undergoing the third phase of clinical trials in 10 countries, including the UAE, Bahrain, Egypt, Jordan, Peru, Argentina. More than 60,000 people were involved in trials abroad. Of these, 40,000 are known to have received two injections and high antibody levels were observed 14 days after the second injection.
